| Size | Price | |
|---|---|---|
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Please refer to the DrugBank entry [DB01593]. Feces and urine are primarily stored in skeletal muscle and bones. Please refer to the DrugBank entry [DB01593]. Metabolism / Metabolites Please refer to the DrugBank entry [DB01593]. Zinc can enter the body through the lungs, skin, and gastrointestinal tract. Intestinal zinc absorption is regulated by the zinc carrier protein CRIP. Zinc can also bind to metallothionein, thus preventing excessive absorption. Zinc is widely distributed in all tissues and tissue fluids, with higher concentrations in the liver, gastrointestinal tract, kidneys, skin, lungs, brain, heart, and pancreas. In the blood, zinc binds to carbonic anhydrase in red blood cells, as well as to albumin, β2-macroglobulin, and amino acids in plasma. Zinc bound to albumin and amino acids can diffuse across tissue membranes. Zinc is ultimately excreted in urine and feces. (L49) Biological Half-Life 280 days |
|---|---|
| Toxicity/Toxicokinetics |
Interactions
High doses of zinc may inhibit intestinal absorption of copper; zinc supplements should be taken at least 2 hours after copper supplements. /Zinc Supplements/ Thiazide diuretics have been found to increase urinary zinc excretion. /Zinc Supplements/ Concurrent consumption of large amounts of fiber, phosphorus, or phytates may reduce zinc absorption by forming non-absorbable complexes; foods containing fiber, phosphorus, or phytates should be consumed at least 2 hours after zinc supplements. /Zinc Supplements/ Some studies have found that folic acid reduces zinc absorption, but not in cases of zinc overdose; other studies have not found an inhibitory effect. /Zinc Supplements/ For more complete data on zinc gluconate (8 interactions in total), please visit the HSDB records page. |
| References | |
| Additional Infomation |
Therapeutic Uses
Veterinary Use: Treatment of bovine dermatophyte infection (caused by Trichophyton verruciformis) with oral formulations containing 20-70% zinc gluconate, 2-10% sulfur, 0.2-1% vitamin A (10⁶ IU), 2-6% methionine, and an inert carrier such as calcium carbonate or flour. Dietary Supplements and Food Additives; Vitamin Tablets Experimental Uses: Adding zinc gluconate to suboptimal doses of Ortho-Gynol gel or Delfen cream improves the vaginal contraceptive efficacy of these products. Experimental Uses: After 24 weeks of administration of vitamin C and zinc (2 g and 60 mg daily), blood lead poisoning levels decreased from 61.6 μg/100 ml to 46.0 μg/100 ml. Post-treatment, hemoglobin levels significantly increased, and serum and whole blood copper levels decreased. For more complete data on the therapeutic uses of zinc gluconate (8 types), please visit the HSDB record page. Drug Warning The potential role of zinc in delaying the progression of age-related macular degeneration has not been established. Zinc salts have no benefit in treating acute intermittent porphyria. /Zinc Supplements/ Zinc injections containing benzyl alcohol as a preservative should not be used on newborns and premature infants. Use of benzyl alcohol in newborns has been associated with fatal toxic syndromes, including metabolic acidosis and damage to the central nervous system, respiratory system, circulatory system, and kidneys. /Zinc Supplements/ Pharmacodynamics Zinc is an essential mineral present in almost all cells of the human body. It promotes the activity of approximately 100 enzymes. Zinc deficiency is often associated with an increased risk of infection. When used to treat the common cold, zinc supplements may interfere with the lysis or adhesion of rhinoviruses and may play a role in protecting cell membranes from microbial toxins and complement damage. |
| Molecular Formula |
C12H22O14ZN
|
|---|---|
| Molecular Weight |
455.67
|
| Exact Mass |
454.03
|
| CAS # |
4468-02-4
|
| PubChem CID |
443445
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
673.6ºC at 760 mmHg
|
| Melting Point |
131ºC
|
| Flash Point |
375.2ºC
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
27
|
| Complexity |
165
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O.[Zn]
|
| InChi Key |
ZSKINHGFQOKUDM-IYEMJOQQSA-N
|
| InChi Code |
InChI=1S/2C6H12O7.Zn/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;/h2*2-5,7-11H,1H2,(H,12,13);/t2*2-,3-,4+,5-;/m11./s1
|
| Chemical Name |
(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoic acid;zinc
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 50 mg/mL (109.73 mM)
DMSO: 50 mg/mL (109.73 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.49 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.49 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1946 mL | 10.9729 mL | 21.9457 mL | |
| 5 mM | 0.4389 mL | 2.1946 mL | 4.3891 mL | |
| 10 mM | 0.2195 mL | 1.0973 mL | 2.1946 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT06120140
Conditions:Carcinoma, Non-Small-Cell LungLink: https://clinicaltrials.gov/ct2/show/NCT05835037
Conditions:Prediabetic State|HyperglycemiaLink: https://clinicaltrials.gov/ct2/show/NCT05085834
Conditions:Inflammation|Cardiovascular Diseases|Zinc Deficiency
Title:The Exploration of the Regulatory Effect of Zinc on Intestinal Flora in Healthy Adults
Status:Completed
updateDate:2024-10-09
Ctid:NCT05597137
Link: https://clinicaltrials.gov/ct2/show/NCT05597137
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT06577285
Conditions:Excessive Gingival DisplayLink: https://clinicaltrials.gov/ct2/show/NCT05527899
Conditions:Zinc DeficiencyLink: https://clinicaltrials.gov/ct2/show/NCT06290219
Conditions:Traumatic Olfactory Nerve Injury With Anosmia (Diagnosis)|Effect of DrugLink: https://clinicaltrials.gov/ct2/show/NCT05096312
Conditions:Acne VulgarisLink: https://clinicaltrials.gov/ct2/show/NCT02856269
Conditions:HIV|InflammationLink: https://clinicaltrials.gov/ct2/show/NCT05098678
Conditions:Behcet SyndromeLink: https://clinicaltrials.gov/ct2/show/NCT04351490
Conditions:SARS-CoV 2Link: https://clinicaltrials.gov/ct2/show/NCT04342728
Conditions:COVID|Corona Virus InfectionLink: https://clinicaltrials.gov/ct2/show/NCT03957720
Conditions:Wilson's DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT02475928
Conditions:Dysgeusia|Liver CirrhosisLink: https://clinicaltrials.gov/ct2/show/NCT01934803
Conditions:HIV Infection|Alcohol UseLink: https://clinicaltrials.gov/ct2/show/NCT02951715
Conditions:Hearing Loss, Noise-Induced|Tinnitus, Noise Induced|Zinc DeficiencyLink: https://clinicaltrials.gov/ct2/show/NCT01984580
Conditions:Barrett's MetaplasiaLink: https://clinicaltrials.gov/ct2/show/NCT01783353
Conditions:Recalcitrant Cutaneous WartsLink: https://clinicaltrials.gov/ct2/show/NCT01576627
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT00495690
Conditions:Pneumonia|Diarrhea|Meningitis|Sepsis|DeathLink: https://clinicaltrials.gov/ct2/show/NCT01309620
Conditions:Diabetes Mellitus, Non-Insulin-DependentLink: https://clinicaltrials.gov/ct2/show/NCT00692224
Conditions:Neonatal JaundiceLink: https://clinicaltrials.gov/ct2/show/NCT00228332
Conditions:Verrucae VulgaresProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
